Abstract
Background: Coronavirus Disease 2019 (COVID-19) is an infectious disease caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). WHO has recommended the use of systemic corticosteroid therapy in patients with severe and critical COVID-19 pneumonia. However, the use of systemic corticosteroids is also a major contributor to hyperglycemia which is a strong prognostic predictor of poor outcome in hospitalized patients with COVID-19. Furthermore, diabetes mellitus (DM) is one of the most widely reported comorbidities in COVID-19 patients which affects the risk of morbidity and mortality and systemic corticosteroids can aggravate hyperglycemia in patients with this comorbidity. Objective : This study aims to determine the effect of DM and blood glucose on mortality in patients with severe COVID-19 pneumonia who received corticosteroids. Methods: The design of this study was an observational retrospective which was conducted on the medical records of COVID-19 patients who received convalescent plasma therapy at RSUD Dr. Saiful Anwar Malang (RSSA). Of the 229 patients who received convalescent plasma therapy and had fairly complete data, there were 85 patients with severe COVID-19 pneumonia who received corticosteroids with blood glucose data for analysis. Results: There were significant differences in mortality rates in DM and non-DM patients (OR 3.091; CI 1.232-7.756; p=0.015) with severe COVID-19 pneumonia who received corticosteroids. Analysis of blood glucose levels shows that the mean random blood glucose (RBG) and initial RBG levels were higher in patients with a death outcome compared to those who lived (mean RBG 176.07 ± 72.0 mg/dl VS 133.23 ± 56.38 mg /dl, p=0.02; initial RBG 198.40 ± 127.13 mg/dl VS 141.57 ± 73.28 mg/dl, p=0.022. Conclusion: DM and blood glucose levels (mean RBG and initial RBG) affect mortality rates in patients with severe COVID-19 pneumonia who are given corticosteroids. Keywords: COVID-19, diabetes mellitus, blood glucose, corticosteroids DOI: 10.7176/JHMN/102-07 Publication date: October 31 st 2022
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
